Business
Gain Therapeutics to Participate at The Citizens Life Sciences Conference
BETHESDA, Md., May 01, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Gene Mack, President and CEO of Gain, will present and participate in one-on-one meetings at The Citizens Life Sciences Conference, being held May 7th-8th in New York City, NY. Details of the presentation are as follows: Dat
About this update from Gain Therapeutics, Inc.
[{"type":"image","alt":"Gain Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Gain Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":150,"height":72,"url":"https://media.zenfs.com/en/globenewswire.com/71d53e58a7e975cfd00a1328d22e0699"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/nsPBXqjXYfLs4XgIgz1iUg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTEwMTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/71d53e58a7e975cfd00a1328d22e0699","width":150,"height":72}},"lazy":false},{"type":"text","content":"BETHESDA, Md., May 01, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Gene Mack, President and CEO of Gain, will present and participate in one-on-one meetings at The Citizens Life Sciences Conference, being held May 7th-8th in New York City, NY.","length":452,"tagName":"p"},{"type":"text","content":"Details of the presentation are as follows:","length":43,"tagName":"p"},{"type":"text","content":"Date: Thursday, May 8, 2025","length":27,"tagName":"p"},{"type":"text","content":"Time: 12:00 p.m. EST","length":20,"tagName":"p"},{"type":"text","content":"Please contact your representative at Citizens if you would like to set up a one-on-one meeting with management.","length":112,"tagName":"p"},{"type":"text","content":"An archived replay of the presentation will be available on the Investors and Media section of the Company’s website at https://gaintherapeutics.com.","length":149,"tagName":"p"},{"type":"text","content":"About Gain Therapeutics, Inc.Gain Therapeutics, Inc. is a clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. Gain’s lead drug candidate, GT-02287 is currently being evaluated for the treatment of Parkinson’s disease with or without a GBA1 mutation in a Phase 1b clinical trial. GT-02287 has further potential in Gaucher’s disease, dementia with Lewy bodies, and Alzheimer’s disease. Gain has multiple undisclosed preclinical assets targeting lysosomal storage disorders, metabolic diseases, and solid tumors.","length":574,"tagName":"p"},{"type":"text","content":"Gain’s unique approach enables the discovery of novel, allosteric sma...